Literature DB >> 29337637

Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?

Conor E Steuer1, Suresh S Ramalingam1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29337637     DOI： 10.1200/JCO.2017.76.8770

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  58 in total

Review 1.  Novel immunotherapy approaches to follicular lymphoma.

Authors:  Christopher R Flowers; John P Leonard; Loretta J Nastoupil
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Methods of measurement for tumor mutational burden in tumor tissue.

Authors:  Bárbara Meléndez; Claude Van Campenhout; Sandrine Rorive; Myriam Remmelink; Isabelle Salmon; Nicky D'Haene
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 3.  Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy.

Authors:  Francesca Fenizia; Raffaella Pasquale; Cristin Roma; Francesca Bergantino; Alessia Iannaccone; Nicola Normanno
Journal:  Transl Lung Cancer Res       Date:  2018-12

4.  High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients.

Authors:  Dedong Cao; Huilin Xu; Ximing Xu; Tao Guo; Wei Ge
Journal:  Oncoimmunology       Date:  2019-06-16       Impact factor: 8.110

5.  Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma.

Authors:  Marius Ilie; Paul Hofman
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 6.  Is There a Role for Immunotherapy in Prostate Cancer?

Authors:  Alessandro Rizzo; Veronica Mollica; Alessia Cimadamore; Matteo Santoni; Marina Scarpelli; Francesca Giunchi; Liang Cheng; Antonio Lopez-Beltran; Michelangelo Fiorentino; Rodolfo Montironi; Francesco Massari
Journal:  Cells       Date:  2020-09-08       Impact factor: 6.600

7.  Depression and inflammation among epidermal growth factor receptor (EGFR) mutant nonsmall cell lung cancer patients.

Authors:  Daniel C McFarland; Devika R Jutagir; Barry Rosenfeld; William Pirl; Andrew H Miller; William Breitbart; Christian Nelson
Journal:  Psychooncology       Date:  2019-05-15       Impact factor: 3.894

8.  A network approach to developing immuno-oncology combinations in Canada.

Authors:  V Higenell; R Fajzel; G Batist; P K Cheema; H L McArthur; B Melosky; D Morris; T M Petrella; R Sangha; M F Savard; S S Sridhar; J Stagg; D J Stewart; S Verma
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

9.  Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.

Authors:  Susan Chi; Kee Kiat Yeo; Chantel Cacciotti; Jungwhan Choi; Sanda Alexandrescu; Mary Ann Zimmerman; Tabitha M Cooney; Christine Chordas; Jessica Clymer
Journal:  J Neurooncol       Date:  2020-07-05       Impact factor: 4.130

Review 10.  Future perspectives: cancer metastases.

Authors:  Stanley P Leong; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-07-23       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.